March 25, 2019
Myriad Genetics Inc. and its directors on Monday shook a proposed securities class action alleging a fraudulent billing of Medicare after a Utah federal judge ruled the suing investor failed to plead that the company's billing was illegal or even an outlier in the industry.
October 31, 2018
Myriad Genetics Inc. and its directors asked a Utah federal judge to throw out a securities fraud class action against them on Tuesday, claiming that investors relied on an "armchair legal opinion" in their failure to adequately argue that the company illegally overbilled Medicare for its cancer testing services.
April 23, 2018
Myriad Genetics Inc. and its executives hid from shareholders that it was overbilling Medicare and Medicaid for a hereditary cancer test in a scheme that eventually drew the U.S. Department of Health and Human Services’ ire and caused the company's stock to slump, an investor in a proposed class action said in Utah federal court.